Rilzabrutinib
- Generic Name
- Rilzabrutinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C36H40FN9O3
- CAS Number
- 1575591-66-0
- Unique Ingredient Identifier
- 5G1WE425BI
- Background
Rilzabrutinib is an oral, reversible covalent inhibitor of Bruton's tyrosine kinase being investigated for the treatment of immune disorders, such as immune thrombocytopenic purpura.
- Associated Conditions
- -
- Associated Therapies
- -
Asthma Drug Companies | Provides Best Medicines
Asthma drug market focuses on quick-relief and long-term control meds; market driven by asthma prevalence, research advancements, and improved diagnostics; projected to reach $64.6 billion by 2033; major companies include Abbott, Merck, GSK, Novartis, Johnson & Johnson, Bristol-Myers Squibb, Sanofi, Pfizer, Teva, and AbbVie.
EADV: New data reinforce Sanofi's innovative approach and leadership
Sanofi presents 39 abstracts at EADV 2024, highlighting Dupixent's impact on IL4/IL13 in AD, PN, CSU, and clinical remission in children with AD. Data also showcase pipeline molecules like amlitelimab and rilzabrutinib in AD and CSU.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath